Close Menu

Tufts

Metabolon will work with Johns Hopkins University and Tufts Medical Center to develop and clinically validate the new blood-based diagnostic.

Scientists from Tufts and Harvard can efficiently deliver Cas9 to human cells with a lipid nanoparticle technology, setting the stage for in vivo delivery.

As Quanterix continues to grow its business, quantifying proteins in single cells could drive its sales in the academic market, CEO Kevin Hrusovsky said.

The deal provides Tufts Health Plan members with access to the ConfirmMDx test for prostate cancer.

Non-invasive prenatal screening tests are not only detecting fetal chromosomal abnormalities, but also some cases of maternal cancer.

The results are the most comprehensive picture so far of the patterns of abnormal NIPT results that could indicate a woman has a higher risk of carrying an unknown tumor.

Around 70 percent of cancer compounds and 40 percent of compounds for all indications are being developed with biomarker data.

The team's dilution experiments suggest Simoa could be thousands of times more sensitive than standard ELISAs in detecting anti-dengue antibodies.

premature infant

Researchers are now seeking collaborators to help develop and commercialize the new assay. 

NEW YORK (GenomeWeb) — A team of researchers from Tufts Medical Center recently assessed the ability of microarrays and next-generation sequencing to profile gene expression in cell-free fetal RNA obtained from amniotic fluid supernatant.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.